Prexton has the objective to develop novel small molecules on mGluR4 as new treatment for Parkinson’s disease.
Prexton is biotech founded as a spin off of Merck Serono, with assets primarily developed at Merck Serono. The objective is to develop small molecules for Parkinson's disease. The target is mGluR4, which has been recently validated in animal models of Parkinson's. All employees of Prexton are formerly Merck Serono's employees. Preclinical and clinical development is outsourced.